CureVac (CVAC)
(Real Time Quote from BATS)
$3.63 USD
-0.16 (-4.22%)
Updated Jul 23, 2024 02:02 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CVAC 3.63 -0.16(-4.22%)
Will CVAC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CVAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CVAC
CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
CVAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
Other News for CVAC
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Quest Diagnostics, Southwest Airlines rise; Simulations Plus falls, Wednesday, 7/3/2024
TOP NEWS: GSK inks licensing deal with CureVac for flu and Covid drugs
CureVac Shareholders Approve Key Resolutions
Bird flu shots to begin in Finland